Compositions and Methods for Inhibiting Gene Expression of LPA
申请人:Arrowhead Pharmaceuticals, Inc.
公开号:US20170096665A1
公开(公告)日:2017-04-06
RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.